Yasuo Miyoshi
Overview
Explore the profile of Yasuo Miyoshi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
174
Citations
2969
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Natori K, Igeta M, Morimoto T, Nagahashi M, Akashi-Tanaka S, Daimon T, et al.
Breast Cancer
. 2025 Feb;
PMID: 39979692
Background: Immune and inflammatory blood parameters have been reported as biomarkers for treatment efficacy. This study aimed to establish a predictive model that includes blood parameters for patients with metastatic...
2.
Oshiro A, Nagahashi M, Togashi Y, Kanaoka H, Hattori A, Tsuchida J, et al.
Anticancer Res
. 2025 Jan;
45(2):789-796.
PMID: 39890192
Background/aim: The Medical Imaging Projection System (MIPS) is a real-time projection mapping system with a highly sensitive fluorescence sensing system. The aim of this study was to investigate the clinical...
3.
Togashi Y, Nagahashi M, Kashima M, Okada C, Kinjo C, Miyazaki A, et al.
Surg Today
. 2025 Jan;
PMID: 39831988
Purpose: To clarify the status of multigene panel testing for suspected hereditary breast cancer in our institute, and disclose the characteristics of the variants detected. Methods: This was a retrospective...
4.
Nagahashi M, Ishikawa E, Nagai T, Kanaoka H, Oshiro A, Togashi Y, et al.
Breast Cancer
. 2025 Jan;
32(2):404-415.
PMID: 39808396
Purpose: The aim of this study was to examine the clinical utility of tumor-infiltrating lymphocytes (TILs) evaluated by "average" and "hot-spot" methods in breast cancer patients. Methods: We examined 367...
5.
Nihira N, Wu W, Hosoi M, Togashi Y, Sunada S, Miyoshi Y, et al.
EMBO Rep
. 2025 Jan;
26(3):635-655.
PMID: 39747659
Immune checkpoint inhibitors against PD-1/PD-L1 are highly effective in immunologically hot tumours such as triple-negative breast cancer, wherein constitutive DNA damage promotes inflammation, while inducing PD-L1 expression to avoid attack...
6.
Wu W, Zhu J, Nihira N, Togashi Y, Goda A, Koike J, et al.
Breast Cancer Res
. 2024 Oct;
26(1):146.
PMID: 39434131
Background: Epigenetic dysregulation affecting oncogenic transcription and DNA damage response is a hallmark of cancer. The histone demethylase KDM4B, a factor regulating these processes, plays important roles in estrogen receptor-mediated...
7.
Ishikawa E, Watanabe T, Kihara T, Kuroiwa M, Komatsu M, Urano S, et al.
Breast Cancer Res Treat
. 2024 Oct;
209(2):291-302.
PMID: 39402242
Purpose: Tumor-infiltrating lymphocyte (TIL) levels are prognostic and predictive factors for breast cancer. Unlike other subtypes, most luminal A breast cancers are immune deserts; however, the underlying mechanisms are poorly...
8.
Mitsuyoshi A, Nagahashi M, Kanaoka H, Oshiro A, Togashi Y, Hattori A, et al.
Int J Clin Oncol
. 2024 Sep;
29(12):1850-1859.
PMID: 39278979
Purpose: The aim of this study was to elucidate the clinical significance of peripheral blood biomarkers, including absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio (NLR), at the end of treatment...
9.
Iwamoto T, Niikura N, Watanabe K, Takeshita T, Kikawa Y, Kobayashi K, et al.
Breast Cancer Res Treat
. 2024 Jun;
208(2):253-262.
PMID: 38922548
Purpose: This study aimed to determine whether the 21-Gene Breast Recurrence Score® assay from primary breast tissue predicts the prognosis of patients with hormone receptor-positive and human epidermal growth factor...
10.
Fehm T, Cottone F, Dunton K, Andre F, Krop I, Park Y, et al.
Lancet Oncol
. 2024 May;
25(5):614-625.
PMID: 38697155
Background: In DESTINY-Breast02, patients with HER2-positive unresectable or metastatic breast cancer who received trastuzumab deruxtecan demonstrated superior progression-free and overall survival compared with those receiving treatment of physician's choice. We...